208 related articles for article (PubMed ID: 19591190)
1. Retro-enantio N-methylated peptides as beta-amyloid aggregation inhibitors.
Grillo-Bosch D; Carulla N; Cruz M; Sánchez L; Pujol-Pina R; Madurga S; Rabanal F; Giralt E
ChemMedChem; 2009 Sep; 4(9):1488-94. PubMed ID: 19591190
[TBL] [Abstract][Full Text] [Related]
2. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease.
Taylor M; Moore S; Mayes J; Parkin E; Beeg M; Canovi M; Gobbi M; Mann DM; Allsop D
Biochemistry; 2010 Apr; 49(15):3261-72. PubMed ID: 20230062
[TBL] [Abstract][Full Text] [Related]
3. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease.
Matharu B; El-Agnaf O; Razvi A; Austen BM
Peptides; 2010 Oct; 31(10):1866-72. PubMed ID: 20633587
[TBL] [Abstract][Full Text] [Related]
4. Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding.
Bateman DA; McLaurin J; Chakrabartty A
BMC Neurosci; 2007 May; 8():29. PubMed ID: 17475015
[TBL] [Abstract][Full Text] [Related]
5. Peptide inhibitors of beta-amyloid aggregation.
Doig AJ
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):533-9. PubMed ID: 17786851
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of protein aggregation and toxicity.
Amijee H; Madine J; Middleton DA; Doig AJ
Biochem Soc Trans; 2009 Aug; 37(Pt 4):692-6. PubMed ID: 19614577
[TBL] [Abstract][Full Text] [Related]
7. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation.
Chafekar SM; Malda H; Merkx M; Meijer EW; Viertl D; Lashuel HA; Baas F; Scheper W
Chembiochem; 2007 Oct; 8(15):1857-64. PubMed ID: 17763487
[TBL] [Abstract][Full Text] [Related]
8. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42.
Liu R; Barkhordarian H; Emadi S; Park CB; Sierks MR
Neurobiol Dis; 2005 Oct; 20(1):74-81. PubMed ID: 16137568
[TBL] [Abstract][Full Text] [Related]
9. Rationally designed dehydroalanine (DeltaAla)-containing peptides inhibit amyloid-beta (Abeta) peptide aggregation.
Rangachari V; Davey ZS; Healy B; Moore BD; Sonoda LK; Cusack B; Maharvi GM; Fauq AH; Rosenberry TL
Biopolymers; 2009 Jun; 91(6):456-65. PubMed ID: 19189374
[TBL] [Abstract][Full Text] [Related]
10. Abeta40 protects non-toxic Abeta42 monomer from aggregation.
Yan Y; Wang C
J Mol Biol; 2007 Jun; 369(4):909-16. PubMed ID: 17481654
[TBL] [Abstract][Full Text] [Related]
11. Eight-residue Abeta peptides inhibit the aggregation and enzymatic activity of Abeta42.
Matsunaga Y; Fujii A; Awasthi A; Yokotani J; Takakura T; Yamada T
Regul Pept; 2004 Aug; 120(1-3):227-36. PubMed ID: 15177941
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models.
van Groen T; Kadish I; Wiesehan K; Funke SA; Willbold D
ChemMedChem; 2009 Feb; 4(2):276-82. PubMed ID: 19072935
[TBL] [Abstract][Full Text] [Related]
13. Selection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation.
Schwarzman AL; Tsiper M; Gregori L; Goldgaber D; Frakowiak J; Mazur-Kolecka B; Taraskina A; Pchelina S; Vitek MP
Amyloid; 2005 Dec; 12(4):199-209. PubMed ID: 16399644
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
15. Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide.
Austen BM; Paleologou KE; Ali SA; Qureshi MM; Allsop D; El-Agnaf OM
Biochemistry; 2008 Feb; 47(7):1984-92. PubMed ID: 18189413
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin inhibition of amyloid beta aggregation and toxicity.
Giunta S; Valli MB; Galeazzi R; Fattoretti P; Corder EH; Galeazzi L
Clin Biochem; 2005 Dec; 38(12):1112-9. PubMed ID: 16183049
[TBL] [Abstract][Full Text] [Related]
17. Galantamine inhibits beta-amyloid aggregation and cytotoxicity.
Matharu B; Gibson G; Parsons R; Huckerby TN; Moore SA; Cooper LJ; Millichamp R; Allsop D; Austen B
J Neurol Sci; 2009 May; 280(1-2):49-58. PubMed ID: 19249060
[TBL] [Abstract][Full Text] [Related]
18. Both the D-(+) and L-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity.
Moore SA; Huckerby TN; Gibson GL; Fullwood NJ; Turnbull S; Tabner BJ; El-Agnaf OM; Allsop D
Biochemistry; 2004 Jan; 43(3):819-26. PubMed ID: 14730987
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
20. The inflammation-sensitive protein alpha 1-anti-chymotrypsin neutralizes fibrillar aggregation and cytotoxicity of the beta-amyloid peptide more effectively than alpha 1-antitrypsin.
Giunta S; Galeazzi R; Marcellini M; Corder EH; Galeazzi L
Clin Biochem; 2007 Aug; 40(12):887-92. PubMed ID: 17512513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
